Gainers
- PLx Pharma PLXP stock increased by 7.5% to $10.17 during Tuesday's after-market session. The company's market cap stands at $280.0 million.
- Cellectar Biosciences CLRB shares increased by 4.99% to $0.73. The company's market cap stands at $44.6 million.
- Celyad Oncology CYAD stock rose 4.76% to $4.62. The market value of their outstanding shares is at $74.3 million.
- Cardiff Oncology CRDF stock moved upwards by 3.62% to $5.71. The market value of their outstanding shares is at $239.6 million.
- OncoSec Medical ONCS stock increased by 3.59% to $1.44. The market value of their outstanding shares is at $56.4 million.
- BioSig Technologies BSGM stock rose 3.35% to $2.77. The market value of their outstanding shares is at $97.8 million.
Losers
- Ensysce Biosciences ENSC stock declined by 5.65% to $3.01 during Tuesday's after-market session. This security traded at a volume of 2.9 million shares come close, making up 336.01% of its average volume over the last 100 days. The market value of their outstanding shares is at $73.0 million.
- NeoGenomics NEO shares decreased by 5.22% to $32.16. This security traded at a volume of 104.5K shares come close, making up 10.42% of its average volume over the last 100 days. The company's market cap stands at $3.9 billion.
- Evoke Pharma EVOK stock decreased by 4.02% to $0.56. The market value of their outstanding shares is at $18.3 million.
- Ekso Bionics Holdings EKSO stock declined by 3.94% to $3.17. The company's market cap stands at $40.1 million.
- Beyond Air XAIR stock fell 3.05% to $10.51. The market value of their outstanding shares is at $279.9 million.
- SINTX Technologies SINT shares declined by 2.98% to $0.76. The market value of their outstanding shares is at $18.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
BSGMBioSig Technologies Inc
$4.801.05%
Edge Rankings
Momentum
99.59
Growth
18.49
Quality
N/A
Value
0.50
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.